Instil Bio, Inc. (TIL) fundamentals score
In January 2026 Instil Bio announceds its wholly owned subsidiary, Axion Bio, Inc., or Axion Bio, was discontinuing development of its former lead product candidate, AXN-2510, a bispecific antibody targeting both programmed death-ligand 1 and the family of vascular endothelial growth factors in solid tumor cancers.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 2.9 out of 10, Unhealthy fundamentals
- Growth: 2.3/10
- Profitability: 1.0/10
- Financial health: 5.2/10
- Earnings quality: 5.5/10
- Valuation: 1.5/10
Scores are calculated from Instil Bio, Inc.’s SEC filings, using the 12 months through 2021-12. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10